loading...

Psoriatic Arthritis Response Criteria (PsARC)

Clegg DO; Alepa FP; Luggen ME; Cohen MR; Makkena R; Haakenson CM; Ward RH; Manaster BJ; Anderson RJ; Ward JR; Silverman SL; Schumacher HR Jr; Cush JJ; Reda DJ; Mejias E; Cannon GW; Weisman MH; Taylor T; Budiman-Mak E; Blackburn WD; Vasey FB; Mahowald ML; Henderson WG

ProQolid

Basic description

Published in 1996

The PsARC was developed as a PsA-specific composite responder index specifically for a study of sulfasalazine in PsA (Clegg DO et Co. 1996). It was first named the PsARC in a subsequent trial of etanercept in PsA (Mease PJ et co. 2000).

A modification of the PsARC using patient and physician global improvement measured by a visual analog scale has been employed and considered acceptable by regulatory agencies (Mease PJ, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double- blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279–89).

Authors

Clegg DO; Alepa FP; Luggen ME; Cohen MR; Makkena R; Haakenson CM; Ward RH; Manaster BJ; Anderson RJ; Ward JR; Silverman SL; Schumacher HR Jr; Cush JJ; Reda DJ; Mejias E; Cannon GW; Weisman MH; Taylor T; Budiman-Mak E; Blackburn WD; Vasey FB; Mahowald ML; Henderson WG

Copyright
No information
Objective
To measure arthritis disease activity
Therapeutic area
  • Skin and Connective Tissue Diseases
  • Musculoskeletal Diseases
Therapeutic indication

Arthritis, Psoriatic

Type of Clinical Outcome Assessment (COA)
  • Composite
PRO and ClinRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39: 2013–20 (PubMed abstract)

Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etan ercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385–90 (PubMed abstract)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us